The Current and Potential Application of Medicinal Cannabis Products in Dentistry

Henry Lowe, Ngeh Toyang, Blair Steele, Joseph Bryant, Wilfred Ngwa, Kaveh Nedamat, Henry Lowe, Ngeh Toyang, Blair Steele, Joseph Bryant, Wilfred Ngwa, Kaveh Nedamat

Abstract

Oral and dental diseases are a major global burden, the most common non-communicable diseases (NCDs), and may even affect an individual's general quality of life and health. The most prevalent dental and oral health conditions are tooth decay (otherwise referred to as dental caries/cavities), oral cancers, gingivitis, periodontitis, periodontal (gum) disease, Noma, oro-dental trauma, oral manifestations of HIV, sensitive teeth, cracked teeth, broken teeth, and congenital anomalies such as cleft lip and palate. Herbs have been utilized for hundreds of years in traditional Chinese, African and Indian medicine and even in some Western countries, for the treatment of oral and dental conditions including but not limited to dental caries, gingivitis and toothaches, dental pulpitis, halitosis (bad breath), mucositis, sore throat, oral wound infections, and periodontal abscesses. Herbs have also been used as plaque removers (chew sticks), antimicrobials, analgesics, anti-inflammatory agents, and antiseptics. Cannabis sativa L. in particular has been utilized in traditional Asian medicine for tooth-pain management, prevention of dental caries and reduction in gum inflammation. The distribution of cannabinoid (CB) receptors in the mouth suggest that the endocannabinoid system may be a target for the treatment of oral and dental diseases. Most recently, interest has been geared toward the use of Cannabidiol (CBD), one of several secondary metabolites produced by C. sativa L. CBD is a known anti-inflammatory, analgesic, anxiolytic, anti-microbial and anti-cancer agent, and as a result, may have therapeutic potential against conditions such burning mouth syndrome, dental anxiety, gingivitis, and possible oral cancer. Other major secondary metabolites of C. sativa L. such as terpenes and flavonoids also share anti-inflammatory, analgesic, anxiolytic and anti-microbial properties and may also have dental and oral applications. This review will investigate the potential of secondary metabolites of C. sativa L. in the treatment of dental and oral diseases.

Keywords: Cannabis sativa L.; cannabinoids; dental caries; gingivitis; periodontitis.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Righolt A.J., Jevdjevic M., Marcenes W., Listl S. Global-, Regional-, and Country-Level Economic Impacts of Dental Diseases in 2015. J. Dent. Res. 2018;97:501–507. doi: 10.1177/0022034517750572.
    1. Robinson S. Jamaica’s Oral Cancer Mortality Rate Is Nearly 100%. Jamaica Observer, 1 April 2017. [(accessed on 2 April 2021)]. Available online: .
    1. Listl S., Galloway J., Mossey P.A., Marcenes W. Global Economic Impact of Dental Diseases. J. Dent. Res. 2015;94:1355–1361. doi: 10.1177/0022034515602879.
    1. James S.L., Abate D., Abate K.H., Abay S.M., Abbafati C., Abbasi N., Abbastabar H., Abd-Allah F., Abdela J., Abdelalim A., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7.
    1. Botelho J., Proença L., Leira Y., Chambrone L., Mendes J.J., Machado V. Economic burden of periodontal disease in Europe and the United states of America—An updated forecast. medRxiv. 2021 doi: 10.1101/2021.01.19.21250090.
    1. World Health Organization Oral Health. [(accessed on 2 April 2021)]. Available online: .
    1. Kassebaum N.J., Bernabé E., Dahiya M., Bhandari B., Murray C.J.L., Marcenes W. Global burden of severe periodontitis in 1990-2010: A systematic review and meta-regression. J. Dent. Res. 2014;93:1045–1053. doi: 10.1177/0022034514552491.
    1. Nazir M., Al-Ansari A., Al-Khalifa K., Alhareky M., Gaffar B., Almas K. Global Prevalence of Periodontal Disease and Lack of Its Surveillance. Sci. World J. 2020;2020:2146160. doi: 10.1155/2020/2146160.
    1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet (Lond. Engl.) 2017;390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2.
    1. Petti S., Glendor U., Andersson L. World traumatic dental injury prevalence and incidence, a meta-analysis-One billion living people have had traumatic dental injuries. Dent. Traumatol. Off. Publ. Int. Assoc. Dent. Traumatol. 2018;34:71–86. doi: 10.1111/edt.12389.
    1. Zheng L.W., Hua H., Cheung L.K. Traditional Chinese medicine and oral diseases: Today and tomorrow. Oral Dis. 2011;17:7–12. doi: 10.1111/j.1601-0825.2010.01706.x.
    1. Meyer-Hamme G., Beckmann K., Radtke J., Efferth T., Greten H.J., Rostock M., Schröder S. A survey of chinese medicinal herbal treatment for chemotherapy-induced oral mucositis. Evid.-Based Complement. Altern. Med. 2013;2013:284959. doi: 10.1155/2013/284959.
    1. Agbor A.M., Naidoo S. A review of the role of African traditional medicine in the management of oral diseases. Afr. J. Tradit. Complement. Altern. Med. 2016;13:133. doi: 10.4314/ajtcam.v13i2.16.
    1. Ayyanar M., Ignacimuthu S. Herbal medicines for wound healing among tribal people in Southern India: Ethnobotanical and Scientific evidences. Int. J. Appl. Res. Nat. Prod. 2009;2:29–42.
    1. Shah N.C. Herbal folk medicines in Northern India. J. Ethnopharmacol. 1982;6:293–301. doi: 10.1016/0378-8741(82)90052-6.
    1. Ganesan A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 2008;12:306–317. doi: 10.1016/j.cbpa.2008.03.016.
    1. Megersa M., Jima T.T., Goro K.K. The Use of Medicinal Plants for the Treatment of Toothache in Ethiopia. Evid.-Based Complement. Altern. Med. 2019;2019:2645174. doi: 10.1155/2019/2645174.
    1. Debbarma M., Pala N.A., Kumar M., Bussmann R.W. TRADITIONAL KNOWLEDGE OF MEDICINAL PLANTS IN TRIBES OF TRIPURA IN NORTHEAST, INDIA. Afr. J. Tradit. Complement. Altern. Med. AJTCAM. 2017;14:156–168. doi: 10.21010/ajtcam.v14i4.19.
    1. Batiha G.E., Alkazmi L.M., Wasef L.G., Beshbishy A.M., Nadwa E.H., Rashwan E.K. Syzygium aromaticum L. (Myrtaceae): Traditional Uses, Bioactive Chemical Constituents, Pharmacological and Toxicological Activities. Biomolecules. 2020;10:202. doi: 10.3390/biom10020202.
    1. Beyi M.W. Ethnobotanical investigation of traditional medicinal plants in Dugda District, Oromia Region. SM J. Med. Plant Stud. 2018;2:1–19. doi: 10.36876/smjmps.1007.
    1. Kefalew A., Asfaw Z., Kelbessa E. Ethnobotany of medicinal plants in Ada’a District, East Shewa Zone of Oromia Regional State, Ethiopia. J. Ethnobiol. Ethnomed. 2015;11:25. doi: 10.1186/s13002-015-0014-6.
    1. Kidane L., Gebremedhin G., Beyene T. Ethnobotanical study of medicinal plants in Ganta Afeshum District, Eastern Zone of Tigray, Northern Ethiopia. J. Ethnobiol. Ethnomed. 2018;14:64. doi: 10.1186/s13002-018-0266-z.
    1. George D., Bhat S.S., Antony B. Comparative evaluation of the antimicrobial efficacy of aloe vera tooth gel and two popular commercial toothpastes: An in vitro study. Gen. Dent. 2009;57:238–241.
    1. Al-Timimi E.A., Al-Casey M. Effect of thymus vulgaris extract on streptococci and mutans streptococci, in comparison to chlorhexidine gluconate (in vivo study) J. Baghdad Coll. Dent. 2012;24:122–127.
    1. Xu J.S., Li Y., Cao X., Cui Y. The effect of eugenol on the cariogenic properties of Streptococcus mutans and dental caries development in rats. Exp. Ther. Med. 2013;5:1667–1670. doi: 10.3892/etm.2013.1066.
    1. Kumar G., Jalaluddin M., Rout P., Mohanty R., Dileep C.L. Emerging trends of herbal care in dentistry. J. Clin. Diagn. Res. JCDR. 2013;7:1827–1829. doi: 10.7860/JCDR/2013/6339.3282.
    1. Elikkottil J., Gupta P., Gupta K. The analgesic potential of cannabinoids. J. Opioid Manag. 2009;5:341–357. doi: 10.5055/jom.2009.0034.
    1. Mikuriya T.H. Marijuana in medicine: Past, present and future. Calif. Med. 1969;110:34–40.
    1. Zuardi A.W. History of cannabis as a medicine: A review. Revista Brasileira de Psiquiatria (Sao Paulo, Brazil: 1999) 2006;28:153–157. doi: 10.1590/S1516-44462006000200015.
    1. Radwan M.M., Ross S.A., Slade D., Ahmed S.A., Zulfiqar F., Elsohly M.A. Isolation and characterization of new Cannabis constituents from a high potency variety. Planta Med. 2008;74:267–272. doi: 10.1055/s-2008-1034311.
    1. Radwan M.M., Elsohly M.A., Slade D., Ahmed S.A., Wilson L., El-Alfy A.T., Khan I.A., Ross S.A. Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry. 2008;69:2627–2633. doi: 10.1016/j.phytochem.2008.07.010.
    1. Radwan M.M., Elsohly M.A., Slade D., Ahmed S.A., Khan I.A., Ross S.A. Biologically active cannabinoids from high-potency Cannabis sativa. J. Nat. Prod. 2009;72:906–911. doi: 10.1021/np900067k.
    1. Barrett M.L., Gordon D., Evans F.J. Isolation from Cannabis sativa L. of cannflavin—A novel inhibitor of prostaglandin production. Biochem. Pharmacol. 1985;34:2019–2024. doi: 10.1016/0006-2952(85)90325-9.
    1. Elsohly M.A., Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78:539–548. doi: 10.1016/j.lfs.2005.09.011.
    1. Pertwee R.G., McPartland J.M., Russo E.B. Non-Phytocannabinoid constituents of cannabis and Herbal Synergy. In: Pertwee R.G., editor. Handbook of Cannabis. 1st ed. Volume 1. Oxford University Press; Oxford, UK: 2014. pp. 280–295.
    1. Flores-Sanchez I.J., Verpoorte R. PKS activities and biosynthesis of cannabinoids and flavonoids in Cannabis sativa L. plants. Plant Cell Physiol. 2008;49:1767–1782. doi: 10.1093/pcp/pcn150.
    1. Booth J.K., Page J.E., Bohlmann J. Terpene synthases from Cannabis sativa. PLoS ONE. 2017;12:e0173911. doi: 10.1371/journal.pone.0173911.
    1. Rea K.A., Casaretto J.A., Al-Abdul-Wahid M.S., Sukumaran A., Geddes-McAlister J., Rothstein S.J., Akhtar T.A. Biosynthesis of cannflavins A and B from Cannabis sativa L. Phytochemistry. 2019;164:162–171. doi: 10.1016/j.phytochem.2019.05.009.
    1. Tomko A.M., Whynot E.G., Ellis L.D., Dupré D.J. Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. Cancers. 2020;12:1985. doi: 10.3390/cancers12071985.
    1. Allaker R.P., Douglas C.W. Novel anti-microbial therapies for dental plaque-related diseases. Int. J. Antimicrob. Agents. 2009;33:8–13. doi: 10.1016/j.ijantimicag.2008.07.014.
    1. Cannabidiol360 How Effective Is CBD for Dental Pain? 6 September 2018. [(accessed on 2 April 2021)]. Available online:
    1. Ward A. CBD Toothpaste Sounds Like a Good Idea but Lacks Conclusive Studies Proving It Is, 3 June 2019. [(accessed on 2 April 2021)]. Available online: .
    1. Sanger B. New Cannabis Toothpaste Has People Losing Their Minds. 12 August 2019. [(accessed on 3 April 2021)]. Available online:
    1. Kaufman H. 5 Benefits of UTILIZING CBD Oral Care. 19 May 2020. [(accessed on 3 April 2021)]. Available online: .
    1. Bourque A. Cannabis for Your Mouth: R&d, Patents, and Your Next Visit to the Dentist. 29 June 2019. [(accessed on 3 April 2021)]. Available online: .
    1. Stahl V., Vasudevan K. Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation. Cureus. 2020;12:e6809. doi: 10.7759/cureus.6809.
    1. Vasudevan K., Stahl V. Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples. J. Cannabis Res. 2020;2:20. doi: 10.1186/s42238-020-00027-z.
    1. Stahl V. Cannabis and Derivatives Thereof for the Treatment of Pain and Inflammation Related with Dental Pulp and Bone Regeneration Related to Dental Jaw Bone Defects. No. US20200222361A1. U.S. Patent. 2020 November 12;
    1. Anastassov G., Changoer L. Oral Care Composition Comprising Cannabinoids. No. US10172786B2. U.S. Patent. 2019 January 8;
    1. 마진열, 임남희, 정윤희, 이주혜, 이지혜, 김Ꙋ익, 유기종 Composition for Prevention or Treatment of Dental Caries Comprising Extract of Cannabis sativa. No. KR20120133135A. South Korea Patent. 2012 December 10;
    1. Van Damme P.A., Anastassov G.E., Lekhram C. Chewing Gum Compositions Comprising Cannabinoids. No. EP2280687B1. U.S. Patent. 2019 February 27;
    1. Di Marzo V. The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 2009;60:77–84. doi: 10.1016/j.phrs.2009.02.010.
    1. Silver R.J. The Endocannabinoid System of Animals. Animals. 2019;9:686. doi: 10.3390/ani9090686.
    1. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 2006;27:73–100. doi: 10.1210/er.2005-0009.
    1. Marsicano G., Lafenêtre P. Roles of the endocannabinoid system in learning and memory. Curr. Top. Behav. Neurosci. 2009;1:201–230. doi: 10.1007/978-3-540-88955-7_8.
    1. Bermudez-Silva F.J., Cardinal P., Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J. Psychopharmacol. (Oxf. Engl.) 2012;26:114–124. doi: 10.1177/0269881111408458.
    1. Woodhams S.G., Sagar D.R., Burston J.J., Chapman V. The role of the endocannabinoid system in pain. Handb. Exp. Pharmacol. 2015;227:119–143. doi: 10.1007/978-3-662-46450-2_7.
    1. Guindon J., Hohmann A.G. The endocannabinoid system and pain. CNS Neurol. Disord. Drug Targets. 2009;8:403–421. doi: 10.2174/187152709789824660.
    1. Gamage T.F., Lichtman A.H. The endocannabinoid system: Role in energy regulation. Pediatr. Blood Cancer. 2012;58:144–148. doi: 10.1002/pbc.23367.
    1. Karasu T., Marczylo T.H., Maccarrone M., Konje J.C. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Hum. Reprod. Update. 2011;17:347–361. doi: 10.1093/humupd/dmq058.
    1. Walker O.S., Holloway A.C., Raha S. The role of the endocannabinoid system in female reproductive tissues. J. Ovarian Res. 2019;12:3. doi: 10.1186/s13048-018-0478-9.
    1. Taylor A.H., Ang C., Bell S.C., Konje J.C. The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Hum. Reprod. Update. 2007;13:501–513. doi: 10.1093/humupd/dmm018.
    1. Pacher P., Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin. Immunopathol. 2009;31:63–77. doi: 10.1007/s00281-009-0145-8.
    1. Manzanares J., Cabañero D., Puente N., García-Gutiérrez M.S., Grandes P., Maldonado R. Role of the endocannabinoid system in drug addiction. Biochem. Pharmacol. 2018;157:108–121. doi: 10.1016/j.bcp.2018.09.013.
    1. Parolaro D., Realini N., Vigano D., Guidali C., Rubino T. The endocannabinoid system and psychiatric disorders. Exp. Neurol. 2010;224:3–14. doi: 10.1016/j.expneurol.2010.03.018.
    1. Vinod K.Y., Hungund B.L. Role of the endocannabinoid system in depression and suicide. Trends Pharmacol. Sci. 2006;27:539–545. doi: 10.1016/j.tips.2006.08.006.
    1. Fakhoury M. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia. Mol. Neurobiol. 2017;54:768–778. doi: 10.1007/s12035-016-9697-5.
    1. Pazos M.R., Núñez E., Benito C., Tolón R.M., Romero J. Role of the endocannabinoid system in Alzheimer’s disease: New perspectives. Life Sci. 2004;75:1907–1915. doi: 10.1016/j.lfs.2004.03.026.
    1. André A., Gonthier M.P. The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment. Int. J. Biochem. Cell Biol. 2010;42:1788–1801. doi: 10.1016/j.biocel.2010.06.002.
    1. Serra G., Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin. Pract. Epidemiol. Ment. Health CP EMH. 2007;3:25. doi: 10.1186/1745-0179-3-25.
    1. Zou S., Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci. 2018;19:833. doi: 10.3390/ijms19030833.
    1. Zou M., Li D., Li L., Wu L., Sun C. Role of the endocannabinoid system in neurological disorders. Int. J. Dev. Neurosci. Off. J. Int. Soc. Dev. Neurosci. 2019;76:95–102. doi: 10.1016/j.ijdevneu.2019.03.002.
    1. Gruden G., Barutta F., Kunos G., Pacher P. Role of the endocannabinoid system in diabetes and diabetic complications. Br. J. Pharmacol. 2016;173:1116–1127. doi: 10.1111/bph.13226.
    1. Pisanti S., Picardi P., D’Alessandro A., Laezza C., Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharmacol. Sci. 2013;34:273–282. doi: 10.1016/j.tips.2013.03.003.
    1. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat. Rev. Drug Discov. 2018;17:623–639. doi: 10.1038/nrd.2018.115.
    1. Alhouayek M., Boldrup L., Fowler C.J. Altered mRNA Expression of Genes Involved in Endocannabinoid Signaling in Squamous Cell Carcinoma of the Oral Tongue. Cancer Investig. 2019;37:327–338. doi: 10.1080/07357907.2019.1638394.
    1. Mandal D.A. Phytocannabinoids. 26 February 2019. [(accessed on 2 April 2021)]. Available online: .
    1. Andre C.M., Hausman J.F., Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front. Plant Sci. 2016;7:19. doi: 10.3389/fpls.2016.00019.
    1. ElSohly M.A., Radwan M.M., Gul W., Chandra S., Galal A. Phytochemistry of Cannabis sativa L. Prog. Chem. Org. Nat. Prod. 2017;103:1–36. doi: 10.1007/978-3-319-45541-9_1.
    1. Demain A.L., Fang A. The natural functions of secondary metabolites. Adv. Biochem. Eng./Biotechnol. 2000;69:1–39. doi: 10.1007/3-540-44964-7_1.
    1. Earlenbaugh E. What Are FLAVONOIDS? 11 March 2021. [(accessed on 2 April 2021)]. Available online:
    1. Bennett P. What Are Cannabis Flavonoids and What Do They Do? 9 February 2018. [(accessed on 3 April 2021)]. Available online: .
    1. Rahn B. What Are Cannabis Terpenes and What Do They Do? 18 November 2019. [(accessed on 3 April 2021)]. Available online: .
    1. Appendino G., Gibbons S., Giana A., Pagani A., Grassi G., Stavri M., Smith E., Rahman M.M. Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. J. Nat. Prod. 2008;71:1427–1430. doi: 10.1021/np8002673.
    1. Rao V.S., Menezes A.M., Viana G.S. Effect of myrcene on nociception in mice. J. Pharm. Pharmacol. 1990;42:877–878. doi: 10.1111/j.2042-7158.1990.tb07046.x.
    1. Johnson J., Theisen E. What Are Terpenes? 6 March 2020. [(accessed on 28 July 2020)]. Available online: .
    1. Valente J., Zuzarte M., Gonçalves M.J., Lopes M.C., Cavaleiro C., Salgueiro L., Cruz M.T. Antifungal, antioxidant and anti-inflammatory activities of Oenanthe crocata L. essential oil. Food Chem. Toxicol. Int. J. Publ. Br. Indus. Biol. Res. Assoc. 2013;62:349–354. doi: 10.1016/j.fct.2013.08.083.
    1. Cavaleiro C., Salgueiro L., Gonçalves M.J., Hrimpeng K., Pinto J., Pinto E. Antifungal activity of the essential oil of Angelica major against Candida, Cryptococcus, Aspergillus and dermatophyte species. J. Nat. Med. 2015;69:241–248. doi: 10.1007/s11418-014-0884-2.
    1. Golfakhrabadi F., Khanavi M., Ostad S.N., Saeidnia S., Vatandoost H., Abai M.R., Hafizi M., Yousefbeyk F., Rad Y.R., Baghenegadian A., et al. Biological activities and composition of ferulago carduchorum essential Oil. J. Arthropod. Borne Dis. 2014;9:104–115.
    1. Kim M.J., Yang K.W., Kim S.S., Park S.M., Park K.J., Kim K.S., Choi Y.H., Cho K.K., Hyun C.G. Chemical composition and anti-inflammation activity of essential oils from Citrus unshiu flower. Nat. Prod. Comm. 2014;9:727–730. doi: 10.1177/1934578X1400900538.
    1. Loizzo M.R., Saab A.M., Tundis R., Statti G.A., Menichini F., Lampronti I., Gambari R., Cinatl J., Doerr H.W. Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chem. Biodiver. 2008;5:461–470. doi: 10.1002/cbdv.200890045.
    1. Vieira-Brock P.L., Vaughan B.M., Vollmer D.L. Comparison of antimicrobial activities of natural essential oils and synthetic fragrances against selected environmental pathogens. Biochim. Open. 2017;5:8–13. doi: 10.1016/j.biopen.2017.09.001.
    1. ElSohly H.N., Turner C.E., Clark A.M., ElSohly M.A. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J. Pharm. Sci. 1982;71:1319–1323. doi: 10.1002/jps.2600711204.
    1. Klahn P. Cannabinoids-Promising Antimicrobial Drugs orIntoxicants with Benefits? Antibiotics. 2020;9:297. doi: 10.3390/antibiotics9060297.
    1. Baron E.P. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache. 2018;58:1139–1186. doi: 10.1111/head.13345.
    1. Russo E.B. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain. Front. Plant Sci. 2019;9:1969. doi: 10.3389/fpls.2018.01969.
    1. Koltai H., Namdar D. Cannabis Phytomolecule ‘Entourage’: From Domestication to Medical Use. Trends Plant Sci. 2020;25:976–984. doi: 10.1016/j.tplants.2020.04.007.
    1. Pellati F., Borgonetti V., Brighenti V., Biagi M., Benvenuti S., Corsi L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. BioMed Res. Int. 2018;2018:1691428. doi: 10.1155/2018/1691428.
    1. Velasco G., Sánchez C., Guzmán M. Anticancer mechanisms of cannabinoids. Curr. Oncol. 2016;23:S23–S32. doi: 10.3747/co.23.3080.
    1. Velasco G., Hernández-Tiedra S., Dávila D., Lorente M. The use of cannabinoids as anticancer agents. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2016;64:259–266. doi: 10.1016/j.pnpbp.2015.05.010.
    1. Guzmán M. Cannabinoids: Potential anticancer agents. Nat. Rev. Cancer. 2003;3:745–755. doi: 10.1038/nrc1188.
    1. Velasco G., Sánchez C., Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer. 2012;12:436–444. doi: 10.1038/nrc3247.
    1. Ramer R., Hinz B. Cannabinoids as Anticancer Drugs. Adv. Pharmacol. (San Diego Calif.) 2017;80:397–436. doi: 10.1016/bs.apha.2017.04.002.
    1. Nagarkatti P., Pandey R., Rieder S.A., Hegde V.L., Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 2009;1:1333–1349. doi: 10.4155/fmc.09.93.
    1. Zurier R.B. Prospects for cannabinoids as anti-inflammatory agents. J. Cell. Biochem. 2003;88:462–466. doi: 10.1002/jcb.10291.
    1. Atalay S., Jarocka-Karpowicz I., Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants. 2019;9:21. doi: 10.3390/antiox9010021.
    1. Costa B., Trovato A.E., Comelli F., Giagnoni G., Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur. J. Pharmacol. 2007;556:75–83. doi: 10.1016/j.ejphar.2006.11.006.
    1. Blaskovich M.A.T., Kavanagh A.M., Elliott A.G., Zhang B., Ramu S., Amado M., Lowe G.J., Hinton A.O., Zuegg J., Beare N., et al. The antimicrobial potential of cannabidiol. Commun. Biol. 2021;4:7. doi: 10.1038/s42003-020-01530-y.
    1. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanus L.O. Cannabidiol—Recent advances. Chem. Biodivers. 2007;4:1678–1692. doi: 10.1002/cbdv.200790147.
    1. Petrosino S., Verde R., Vaia M., Allarà M., Iuvone T., Di Marzo V. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. J. Pharmacol. Exp. Ther. 2018;365:652–663. doi: 10.1124/jpet.117.244368.
    1. Izzo A.A., Capasso R., Aviello G., Borrelli F., Romano B., Piscitelli F., Gallo L., Capasso F., Orlando P., Di Marzo V. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br. J. Pharmacol. 2012;166:1444–1460. doi: 10.1111/j.1476-5381.2012.01879.x.
    1. Davis W.M., Hatoum N.S. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen. Pharmacol. 1983;14:247–252. doi: 10.1016/0306-3623(83)90004-6.
    1. Turner C.E., Elsohly M.A. Biological activity of cannabichromene, its homologs and isomers. J. Clin. Pharmacol. 1981;21:283S–291S. doi: 10.1002/j.1552-4604.1981.tb02606.x.
    1. DeLong G.T., Wolf C.E., Poklis A., Lichtman A.H. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. Drug Alcohol Depend. 2010;112:126–133. doi: 10.1016/j.drugalcdep.2010.05.019.
    1. Wirth P.W., Watson E.S., ElSohly M., Turner C.E., Murphy J.C. Anti-inflammatory properties of cannabichromene. Life Sci. 1980;26:1991–1995. doi: 10.1016/0024-3205(80)90631-1.
    1. Lygos CBX Adds Cannabichromene to Its Growing Portfolio of High-Quality, Pure and SUSTAINABLE Cannabinoids.19 January 2021. [(accessed on 3 April 2021)]. Available online:
    1. Nachnani R., Raup-Konsavage W.M., Vrana K.E. The Pharmacological Case for Cannabigerol. J. Pharmacol. Exp. Ther. 2021;376:204–212. doi: 10.1124/jpet.120.000340.
    1. Farha M.A., El-Halfawy O.M., Gale R.T., MacNair C.R., Carfrae L.A., Zhang X., Jentsch N.G., Magolan J., Brown E.D. Uncovering the Hidden Antibiotic Potential of Cannabis. ACS Infect. Dis. 2020;6:338–346. doi: 10.1021/acsinfecdis.9b00419.
    1. Di Giacomo V., Chiavaroli A., Recinella L., Orlando G., Cataldi A., Rapino M., Di Valerio V., Ronci M., Leone S., Brunetti L., et al. Antioxidant and Neuroprotective Effects Induced by Cannabidiol and Cannabigerol in Rat CTX-TNA2 Astrocytes and Isolated Cortexes. Int. J. Mol. Sci. 2020;21:3575. doi: 10.3390/ijms21103575.
    1. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J. Neurochem. 2002;80:448–456. doi: 10.1046/j.0022-3042.2001.00716.x.
    1. Stone N.L., Murphy A.J., England T.J., O’Sullivan S.E. A systematic review of minor phytocannabinoids with promising neuroprotective potential. Br. J. Pharmacol. 2020;177:4330–4352. doi: 10.1111/bph.15185.
    1. Nuutinen T. Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus. Eur. J. Med. Chem. 2018;157:198–228. doi: 10.1016/j.ejmech.2018.07.076.
    1. Salehi B., Upadhyay S., Erdogan Orhan I., Kumar Jugran A., Jayaweera S.L.D., Dias D.A., Sharopov F., Taheri Y., Martins N., Baghalpour N., et al. Therapeutic Potential of α- and β-Pinene: A Miracle Gift of Nature. Biomolecules. 2019;9:738. doi: 10.3390/biom9110738.
    1. Karas J.A., Wong L., Paulin O., Mazeh A.C., Hussein M.H., Li J., Velkov T. The Antimicrobial Activity of Cannabinoids. Antibiotics. 2020;9:406. doi: 10.3390/antibiotics9070406.
    1. Iseppi R., Brighenti V., Licata M., Lambertini A., Sabia C., Messi P., Pellati F., Benvenuti S. Chemical Characterization and Evaluation of the Antibacterial Activity of Essential Oils from Fibre-Type Cannabis sativa L. (Hemp) Molecules. 2019;24:2302. doi: 10.3390/molecules24122302.
    1. Gallily R., Yekhtin Z., Hanuš L.O. The Anti-Inflammatory Properties of Terpenoids from Cannabis. Cannabis Cannabinoid Res. 2018;3:282–290. doi: 10.1089/can.2018.0014.
    1. Rogerio A.P., Andrade E.L., Leite D.F., Figueiredo C.P., Calixto J.B. Preventive and therapeutic anti-inflammatory properties of the sesquiterpene alpha-humulene in experimental airways allergic inflammation. Br. J. Pharmacol. 2009;158:1074–1087. doi: 10.1111/j.1476-5381.2009.00177.x.
    1. Chaves J.S., Leal P.C., Pianowisky L., Calixto J.B. Pharmacokinetics and tissue distribution of the sesquiterpene alpha-humulene in mice. Planta Med. 2008;74:1678–1683. doi: 10.1055/s-0028-1088307.
    1. Satsu H., Matsuda T., Toshimitsu T., Mori A., Mae T., Tsukagawa M., Kitahara M., Shimizu M. Regulation of interleukin-8 secretion in human intestinal epithelial Caco-2 cells by alpha-humulene. BioFactors (Oxf. Engl.) 2004;21:137–139. doi: 10.1002/biof.552210127.
    1. Legault J., Pichette A. Potentiating effect of beta-caryophyllene on anticancer activity of alpha-humulene, isocaryophyllene and paclitaxel. J. Pharm. Pharmacol. 2007;59:1643–1647. doi: 10.1211/jpp.59.12.0005.
    1. Bouajaj S., Benyamna A., Bouamama H., Romane A., Falconieri D., Piras A., Marongiu B. Antibacterial, allelopathic and antioxidant activities of essential oil of Salvia officinalis L. growing wild in the Atlas Mountains of Morocco. Nat. Prod. Res. 2013;27:1673–1676. doi: 10.1080/14786419.2012.751600.
    1. Dahham S.S., Tabana Y.M., Iqbal M.A., Ahamed M.B., Ezzat M.O., Majid A.S., Majid A.M. The Anticancer, Antioxidant and Antimicrobial Properties of the Sesquiterpene β-Caryophyllene from the Essential Oil of Aquilaria crassna. Molecules. 2015;20:11808–11829. doi: 10.3390/molecules200711808.
    1. Pieri F.A., Souza M.C., Vermelho L.L., Vermelho M.L., Perciano P.G., Vargas F.S., Borges A.P., da Veiga-Junior V.F., Moreira M.A. Use of β-caryophyllene to combat bacterial dental plaque formation in dogs. BMC Vet. Res. 2016;12:216. doi: 10.1186/s12917-016-0842-1.
    1. Hanuš L.O., Hod Y. Terpenes/Terpenoids in Cannabis: Are They Important? Med. Cannabis Cannabinoids. 2020;3:25–60. doi: 10.1159/000509733.
    1. Zahi M.R., El Hattab M., Liang H., Yuan Q. Enhancing the antimicrobial activity of d-limonene nanoemulsion with the inclusion of ε-polylysine. Food Chem. 2017;221:18–23. doi: 10.1016/j.foodchem.2016.10.037.
    1. Han Y., Sun Z., Chen W. Antimicrobial Susceptibility and Antibacterial Mechanism of Limonene against Listeria monocytogenes. Molecules. 2019;25:33. doi: 10.3390/molecules25010033.
    1. Espina L., Gelaw T.K., de Lamo-Castellví S., Pagán R., García-Gonzalo D. Mechanism of bacterial inactivation by (+)-limonene and its potential use in food preservation combined processes. PLoS ONE. 2013;8:e56769. doi: 10.1371/journal.pone.0056769.
    1. Lima N.G., De Sousa D.P., Pimenta F.C., Alves M.F., De Souza F.S., Macedo R.O., Cardoso R.B., de Morais L.C., Melo Diniz M., de Almeida R.N. Anxiolytic-like activity and GC-MS analysis of (R)-(+)-limonene fragrance, a natural compound found in foods and plants. Pharmacol. Biochem. Behav. 2013;103:450–454. doi: 10.1016/j.pbb.2012.09.005.
    1. de Sousa D.P. Analgesic-like activity of essential oils constituents. Molecules. 2011;16:2233–2252. doi: 10.3390/molecules16032233.
    1. Roberto D., Micucci P., Sebastian T., Graciela F., Anesini C. Antioxidant activity of limonene on normal murine lymphocytes: Relation to H2O2 modulation and cell proliferation. Basic Clin. Pharmacol. Toxicol. 2010;106:38–44. doi: 10.1111/j.1742-7843.2009.00467.x.
    1. Held S., Schieberle P., Somoza V. Characterization of α-Terpineol as an anti-inflammatory component of orange juice by in vitro studies using oral buccal cells. J. Agric. Food Chem. 2007;55:8040–8046. doi: 10.1021/jf071691m.
    1. Quintans-Júnior L.J., Oliveira M.G., Santana M.F., Santana M.T., Guimarães A.G., Siqueira J.S., Almeida R.N. α-Terpineol reduces nociceptive behavior in mice. Pharm. Biol. 2011;49:583–586. doi: 10.3109/13880209.2010.529616.
    1. Forget Aspirin, These Marijuana-Based Painkillers Are 30 Times More Powerful. 26 July 2019. [(accessed on 4 April 2021)]. Available online: .
    1. Cannabis CannaFlavins 30x Stronger Than Aspirin in Cell Experiment. 27 December 2019. [(accessed on 4 April 2021)]. Available online:
    1. Barrett M.L., Scutt A.M., Evans F.J. Cannflavin A and B, prenylated flavones from Cannabis sativa L. Experientia. 1986;42:452–453. doi: 10.1007/BF02118655.
    1. Erridge S., Mangal N., Salazar O., Pacchetti B., Sodergren M.H. Cannflavins—From plant to patient: A scoping review. Fitoterapia. 2020;146:104712. doi: 10.1016/j.fitote.2020.104712.
    1. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394:277–281. doi: 10.1038/28393.
    1. Pisanti S., Malfitano A.M., Grimaldi C., Santoro A., Gazzerro P., Laezza C., Bifulco M. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract. Res. Clin. Endocrinol. Metab. 2009;23:117–131. doi: 10.1016/j.beem.2009.02.001.
    1. Conti S., Costa B., Colleoni M., Parolaro D., Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 2002;135:181–187. doi: 10.1038/sj.bjp.0704466.
    1. Chakravarti B., Ravi J., Ganju R.K. Cannabinoids as therapeutic agents in cancer: Current status and future implications. Oncotarget. 2014;5:5852–5872. doi: 10.18632/oncotarget.2233.
    1. Sumariwalla P.F., Gallily R., Tchilibon S., Fride E., Mechoulam R., Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 2004;50:985–998. doi: 10.1002/art.20050.
    1. Xu H., Cheng C.L., Chen M., Manivannan A., Cabay L., Pertwee R.G., Coutts A., Forrester J.V. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol. 2007;82:532–541. doi: 10.1189/jlb.0307159.
    1. Yuill M.B., Hale D.E., Guindon J., Morgan D.J. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Mol. Pain. 2017;13:1744806917728227. doi: 10.1177/1744806917728227.
    1. Müller L., Radtke A., Decker J., Koch M., Belge G. The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines. Anticancer Res. 2017;37:6341–6345. doi: 10.21873/anticanres.12086.
    1. Roberto D., Klotz L.H., Venkateswaran V. Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner. Prostate. 2019;79:151–159. doi: 10.1002/pros.23720.
    1. Borsani E., Majorana A., Cocchi M.A., Conti G., Bonadeo S., Padovani A., Lauria G., Bardellini E., Rezzani R., Rodella L.F. Epithelial expression of vanilloid and cannabinoid receptors: A potential role in burning mouth syndrome pathogenesis. Histol. Histopathol. 2014;29:523–533. doi: 10.14670/HH-29.10.523.
    1. Hipkaeo W., Watanabe M., Kondo H. Localization of Cannabinoid Receptor 1 (CB1) in Submandibular and Sublingual Salivary Glands of Mice throughout Postnatal Development. Int. J. Morphol. 2015;33:695–700. doi: 10.4067/S0717-95022015000200044.
    1. Prestifilippo J.P., Fernández-Solari J., Cal C.D.L., Iribarne M., Suburo A.M., Rettori V., McCann S.M., Elverdin J.C. Inhibition of Salivary Secretion by Activation of Cannabinoid Receptors. Exp. Biol. Med. 2006;231:1421–1429. doi: 10.1177/153537020623100816.
    1. Kopach O., Vats J., Netsyk O., Voitenko N., Irving A., Fedirko N. Cannabinoid receptors in submandibular acinar cells: Functional coupling between saliva fluid and electrolytes secretion and Ca2+ signalling. Pt 8J. Cell Sci. 2012;125:1884–1895. doi: 10.1242/jcs.088930.
    1. Kakoei S., Parirokh M., Nakhaee N., Jamshidshirazi F., Rad M., Kakooei S. Prevalence of toothache and associated factors: A population-based study in Southeast Iran. Iran. Endod. J. 2013;8:123–128.
    1. Cohen L.A., Bonito A.J., Akin D.R., Manski R.J., Macek M.D., Edwards R.R., Cornelius L.J. Toothache pain: A comparison of visits to physicians, emergency departments and dentists. J. Am. Dent. Assoc. 2008;139:1205–1216. doi: 10.14219/jada.archive.2008.0336.
    1. Vučković S., Srebro D., Vujović K.S., Vučetić Č., Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Front. Pharmacol. 2018;9:1259. doi: 10.3389/fphar.2018.01259.
    1. Royal Queen Seeds Can CBD Help Relieve Toothache? 25 November 2019. [(accessed on 6 April 2021)]. Available online: .
    1. Mayo Foundation for Medical Education and Research Burning mouth syndrome. Mayo Clinic, 14 February 2019. [(accessed on 6 April 2021)]. Available online: .
    1. Sun A., Wu K.M., Wang Y.P., Lin H.P., Chen H.M., Chiang C.P. Burning mouth syndrome: A review and update. J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol. 2013;42:649–655. doi: 10.1111/jop.12101.
    1. Pereira S.R., Tello Velasquez J., Duggan S., Ivanisevic B., McKenna J.P., McCreary C., Downer E.J. Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids. Eur. J. Neurosci. 2020 doi: 10.1111/ejn.14712.
    1. Study: Cannabis Extracts Mitigate Symptoms of Burning Mouth Syndrome. NORML, 10 May 2021. [(accessed on 6 April 2021)]. Available online:
    1. Dowden A. Cannabis Oil May Help Burning Mouth Syndrome. , 13 November 2020. [(accessed on 6 April 2021)]. Available online: .
    1. Gambino A., Cabras M., Panagiotakos E., Calvo F., Macciotta A., Cafaro A., Suria M., Haddad G.E., Broccoletti R., Arduino P.G. Evaluating the Suitability and Potential Efficiency of Cannabis sativa Oil for Patients with Primary Burning Mouth Syndrome: A Prospective, Open-Label, Single-Arm Pilot Study. Pain Med. (Malden Mass.) 2021;22:142–151. doi: 10.1093/pm/pnaa318.
    1. Sunariani J., Wijaksana I.K.E., Setiawatie E.M. The Role of Vanilloid and Cannabinoid Receptors in Taste and Pain Perception in Burning Mouth Syndrome; Proceedings of the 7th International Meeting and the 4th Joint Scientific Meeting in Dentistry; Surabaya, Indonesia. 5–7 October 2017;
    1. Bare L.C., Dundes L. Strategies for combating dental anxiety. J. Dent. Educ. 2004;68:1172–1177. doi: 10.1002/j.0022-0337.2004.68.11.tb03862.x.
    1. Berggren U., Meynert G. Dental fear and avoidance: Causes, symptoms, and consequences. J. Am. Dent. Assoc. 1984;109:247–251. doi: 10.14219/jada.archive.1984.0328.
    1. Townend E., Dimigen G., Fung D. A clinical study of child dental anxiety. Behav. Res. Ther. 2000;38:31–46. doi: 10.1016/S0005-7967(98)00205-8.
    1. Minja I.K., Kahabuka F.K. Dental Anxiety and Its Consequences to Oral Health Care Attendance and Delivery. Anxiety Disord. From Childhood Adulthood. 2019 doi: 10.5772/intechopen.82175.
    1. Cohen S.M., Fiske J., Newton J.T. The impact of dental anxiety on daily living. Br. Dent. J. 2000;189:385–390. doi: 10.1038/sj.bdj.4800777.
    1. Hällström T., Halling A. Prevalence of dentistry phobia and its relation to missing teeth, alveolar bone loss and dental care habits in an urban community sample. Acta Psychiatr. Scand. 1984;70:438–446. doi: 10.1111/j.1600-0447.1984.tb01232.x.
    1. Locker D., Liddell A. Clinical correlates of dental anxiety among older adults. Community Dent. Oral Epidemiol. 1992;20:372–375. doi: 10.1111/j.1600-0528.1992.tb00702.x.
    1. Hakeberg M., Berggren U., Gröndahl H.G. A radiographic study of dental health in adult patients with dental anxiety. Community Dent. Oral Epidemiol. 1993;21:27–30. doi: 10.1111/j.1600-0528.1993.tb00714.x.
    1. Appukuttan D.P. Strategies to manage patients with dental anxiety and dental phobia: Literature review. Clin. Cosmet. Investig. Dent. 2016;8:35–50. doi: 10.2147/CCIDE.S63626.
    1. Sharif M.O. Dental anxiety: Detection and management. J. Appl. Oral Sci. Rev. FOB. 2010;18 doi: 10.1590/s1678-77572010000200001.
    1. Wide Boman U., Carlsson V., Westin M., Hakeberg M. Psychological treatment of dental anxiety among adults: A systematic review. Pt 2Eur. J. Oral Sci. 2013;121:225–234. doi: 10.1111/eos.12032.
    1. Facco E., Zanette G., Casiglia E. The role of hypnotherapy in dentistry. SAAD Dig. 2014;30:3–6.
    1. Roberts K. Hypnosis in dentistry. Dent. Update. 2006;33:312–314. doi: 10.12968/denu.2006.33.5.312.
    1. Patel B., Potter C., Mellor A.C. The use of hypnosis in dentistry: A review. Dent. Update. 2000;27:198–202. doi: 10.12968/denu.2000.27.4.198.
    1. Armfield J.M., Heaton L.J. Management of fear and anxiety in the dental clinic: A review. Aust. Dent. J. 2013;58:390–531. doi: 10.1111/adj.12118.
    1. Chebbi Y. Cbd: A Natural Remedy for Dental Anxiety. 24 July 2020. [(accessed on 1 April 2021)]. Available online:
    1. Cohen P. Treating Dental Anxiety with Natural Remedies Like CBD. 15 February 2019. [(accessed on 6 April 2021)]. Available online:
    1. Özdemir B., Shi B., Bantleon H.P., Moritz A., Rausch-Fan X., Andrukhov O. Endocannabinoids and inflammatory response in periodontal ligament cells. PLoS ONE. 2014;9:e107407. doi: 10.1371/journal.pone.0107407.
    1. Jäger A., Setiawan M., Beins E., Schmidt-Wolf I., Konermann A. Analogous modulation of inflammatory responses by the endocannabinoid system in periodontal ligament cells and microglia. Head Face Med. 2020;16:26. doi: 10.1186/s13005-020-00244-0.
    1. Kozono S., Matsuyama T., Biwasa K.K., Kawahara K.-I., Nakajima Y., Yoshimoto T., Yonamine Y., Kadomatsu H., Tancharoen S., Hashiguchi T., et al. Involvement of the endocannabinoid system in periodontal healing. Biochem. Biophys. Res. Commun. 2010;394:928–933. doi: 10.1016/j.bbrc.2010.03.080.
    1. Van Klingeren B., Ten Ham M. Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek. 1976;42:9–12. doi: 10.1007/BF00399444.
    1. Dariš B., Tancer Verboten M., Knez Ž., Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosn. J. Basic Med. Sci. 2019;19:14–23. doi: 10.17305/bjbms.2018.3532.
    1. Hajishengallis G., Chavakis T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat. Rev. Immunol. 2021;21:426–440. doi: 10.1038/s41577-020-00488-6.
    1. Mammana S., Cavalli E., Gugliandolo A., Silvestro S., Pollastro F., Bramanti P., Mazzon E. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol. Medicina (Kaunas, Lithuania) 2019;55:747. doi: 10.3390/medicina55110747.
    1. Sukumar K., Tadepalli A. Nexus between COVID-19 and periodontal disease. J. Int. Med. Res. 2021;49 doi: 10.1177/03000605211002695.
    1. Marouf N., Cai W., Said K.N., Daas H., Diab H., Chinta V.R., Hssain A.A., Nicolau B., Sanz M., Tamimi F. Association between periodontitis and severity of COVID-19 infection: A case–control study. J. Clin. Periodontol. 2021;48:483–491. doi: 10.1111/jcpe.13435.
    1. Mucositis. [(accessed on 1 April 2021)]. Available online:
    1. Cuba L.F., Salum F.G., Cherubini K., Figueiredo M.A.Z. Cannabidiol: An alternative therapeutic agent for oral mucositis? J. Clin. Pharm. Ther. 2017;42:245–250. doi: 10.1111/jcpt.12504.
    1. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009;156:397–411. doi: 10.1111/j.1476-5381.2008.00048.x.
    1. Hanlon K.E., Lozano-Ondoua A.N., Umaretiya P.J., Symons-Liguori A.M., Chandramouli A., Moy J.K., Kwass W.K., Mantyh P.W., Nelson M.A., Vanderah T.W. Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent. Breast Cancer. 2016;8:59–71. doi: 10.2147/BCTT.S100393.
    1. Zhu L.X., Sharma S., Stolina M., Gardner B., Roth M.D., Tashkin D.P., Dubinett S.M. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 2000;165:373–380. doi: 10.4049/jimmunol.165.1.373.
    1. McKallip R.J., Nagarkatti M., Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 2005;174:3281–3289. doi: 10.4049/jimmunol.174.6.3281.
    1. Marcu J.P., Christian R.T., Lau D., Zielinski A.J., Horowitz M.P., Lee J., Pakdel A., Allison J., Limbad C., Moore D.H., et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 2010;9:180–189. doi: 10.1158/1535-7163.MCT-09-0407.
    1. Sharma M., Hudson J.B., Adomat H., Guns E., Cox M.E. In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines. Pharmacol. Pharm. 2014;05:806–820. doi: 10.4236/pp.2014.58091.
    1. Solinas M., Massi P., Cinquina V., Valenti M., Bolognini D., Gariboldi M., Monti E., Rubino T., Parolaro D. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS ONE. 2013;8:e76918. doi: 10.1371/journal.pone.0076918.
    1. Shrivastava A., Kuzontkoski P.M., Groopman J.E., Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol. Cancer Ther. 2011;10:1161–1172. doi: 10.1158/1535-7163.MCT-10-1100.
    1. Cridge B.J., Rosengren R.J. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag. Res. 2013;5:301–313. doi: 10.2147/CMAR.S36105.
    1. McAllister S.D., Soroceanu L., Desprez P.Y. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. J. Neuroimmune Pharmacol. 2015;10:255–267. doi: 10.1007/s11481-015-9608-y.
    1. Gruetzmacher K. The Pros and Cons of Using Medical Marijuana to Treat Oral Cancer. 13 September 2017. [(accessed on 6 April 2021)]. Available online:
    1. CBD Oil for Oral Hygiene. 5 April 2018. [(accessed on 6 April 2021)]. Available online: .
    1. CBD in Dentistry—Can Cannabis Cure Cavities? 13 October 2017. [(accessed on 6 April 2021)]. Available online:
    1. Rettori E., De Laurentiis A., Zorrilla Zubilete M., Rettori V., Elverdin J.C. Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat. Neuroimmunomodulation. 2012;19:293–303. doi: 10.1159/000339113.
    1. Nakajima Y., Furuichi Y., Biswas K.K., Hashiguchi T., Kawahara K., Yamaji K., Uchimura T., Izumi Y., Maruyama I. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett. 2006;580:613–619. doi: 10.1016/j.febslet.2005.12.079.
    1. Arney K. Cannabis, Cannabinoids and Cancer—The Evidence So Far. Cancer News, 25 July 2012. [(accessed on 6 April 2021)]. Available online:
    1. Vatican J. Why Use CBD Oil Before Visiting the Dentist. Medical Daily, 22 May 2019. [(accessed on 6 April 2021)]. Available online: .
    1. Burhenne M. CBD Oil Benefits for Better Dental & Overall Health. 30 August 2019. [(accessed on 1 April 2021)]. Available online: .
    1. Sybertz A. CBD for Dental Pain, Anxiety, and Problems: Does It Work? The Healthy, 7 May 2021. [(accessed on 6 April 2021)]. Available online:
    1. What Are the Benefits of Hemp Seed Oil in Toothpaste? Humming Hemp, 3 March 2021. [(accessed on 6 April 2021)]. Available online:
    1. Administrator CBD and Bone Fracture Healing: The Best Data Published for Medical Marijuana in Fifty Years. BioTrack: The Leading Seed-to-Sale Cannabis Software. [(accessed on 6 April 2021)]. Available online:
    1. McNamee D. Marijuana ‘Helps Bones to Heal’. 20 July 2015. [(accessed on 6 April 2021)]. Available online: .
    1. Bab I., Zimmer A., Melamed E. Cannabinoids and the skeleton: From marijuana to reversal of bone loss. Ann. Med. 2009;41:560–567. doi: 10.1080/07853890903121025.
    1. Stahl V. Cannabis and Derivatives Thereof for the Treatment of Pain and Inflammation Related with Dental Pulp and Bone Regeneration Related to Dental Jaw Bone Defects. No. WO2019030762A3. U.S. Patent. 2019 March 19;
    1. Napimoga M.H., Benatti B.B., Lima F.O., Alves P.M., Campos A.C., Pena-Dos-Santos D.R., Severino F.P., Cunha F.Q., Guimarães F.S. Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int. Immunopharmacol. 2009;9:216–222. doi: 10.1016/j.intimp.2008.11.010.
    1. Ways CBD Takes Care of Your Salivary Gland Infection. 31 August 2019. [(accessed on 6 April 2021)]. Available online:
    1. Benefits of CBG for Salivary Gland Infection: Salivary Gland Inflammation. 2019. [(accessed on 12 May 2019)]. Available online:
    1. CBD for Temporomandibular Joint Disorder (TMJ). 24 January 2020. [(accessed on 6 April 2021)]. Available online:
    1. Qian H., Jin Z., Li S., Huo N., Han C., Sang H. Activation of CB2 cannabinoid receptors: A novel therapeutic strategy to accelerate osseointegration of dental implants. Med. Hypotheses. 2009;72:311–313. doi: 10.1016/j.mehy.2008.09.047.
    1. Werz O., Seegers J., Schaible A.M., Weinigel C., Barz D., Koeberle A., Allegrone G., Pollastro F., Zampieri L., Grassi G., et al. Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. PharmaNutrition. 2014;2:53–60. doi: 10.1016/j.phanu.2014.05.001.
    1. Richter N. What Are Flavonoids? Comprehensive Guide. 10 March 2020. [(accessed on 28 July 2020)]. Available online: .

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj